The tumor ablation market was valued at $1.6 billion in 2023, and is estimated to reach $7.5 billion by 2035, growing at a CAGR of 13.6% from 2024 to 2035. Tumor ablation is a medical procedure used to treat cancer by destroying tumor cells without the need for traditional surgery. This technique involves the targeted application of energy to the tumor site to destroy or shrink cancerous growths. Several methods are used for tumor ablation, including thermal ablation techniques such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. These methods work by either heating or freezing the tumor cells, effectively killing them or halting their growth. Tumor ablation is typically used for tumors that are difficult to reach surgically, located in sensitive areas, or for patients who may not be candidates for conventional surgery due to their health conditions. It serves as a complementary treatment alongside other cancer therapies such as chemotherapy or radiation. The rising global prevalence of cancer is a major factor contributing to the growth of the tumor ablation market.
For instance, the World Health Organization (WHO), predicted 35 million new cancer cases in 2050, a 77% increase from the estimated 20 million cases in 2022. This growing incidence of cancer increased the demand for effective treatment options, including tumor ablation. Ablation therapies are particularly useful in treating tumors that are difficult to access surgically or those that are located in sensitive areas, such as the liver, lungs, kidneys, and prostate. As the number of cancer patients continues to rise, the need for innovative and less invasive treatment options, such as tumor ablation, are expected to continue to grow. In addition, rise in demand for minimally invasive procedures is another significant driver for the tumor ablation market. As patients and healthcare providers become more aware of the benefits of minimally invasive techniques, such as reduced hospital stays, faster recovery, and fewer complications, the preference for these procedures has grown. Tumor ablation procedures, being minimally invasive, cater to this demand, providing a treatment option that are performed with smaller incisions or even through percutaneous (needle-based) approaches. These factors make tumor ablation particularly appealing to both patients and healthcare providers, leading to a shift toward these therapies in clinical practice. Furthermore, rises in government initiatives aimed at cancer research and treatment are another factor fueling market growth.
Many governments and organizations are increasing funding for cancer-related research, which has led to the development of more effective and precise tumor ablation technologies. The U.S. National Cancer Institute (NCI), for example, has been actively involved in funding studies related to innovative cancer treatments, including tumor ablation. In addition, several regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are working to streamline the approval processes for new tumor ablation technologies, which has encouraged further market development. For instance, in March 2024, Medtronic plc, a global leader in healthcare technology announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. Thus, rise in the number of product approvals further drives market growth. However, high cost of ablation procedures and equipment, which limits accessibility, particularly in low- and middleincome countries, thereby restricts market growth. These procedures often require advanced technology, which can be expensive for healthcare providers to adopt and maintain, making it difficult for many patients to afford. In addition, the limited reimbursement policies in certain regions can restrict patient access to these therapies. Another restraint is the potential for complications associated with ablation procedures, such as injury to surrounding healthy tissues or inadequate treatment of larger or more complex tumors which further limits the market growth.
On the other hand, the ongoing advancements in ablation technologies, such as the development of more precise and efficient devices, create opportunities to improve treatment outcomes and expand the range of treatable tumors. There is also considerable potential for market expansion in emerging economies, where improving healthcare infrastructure and increasing awareness about cancer treatments are driving the adoption of advanced medical technologies such as tumor ablation. These opportunities collectively provide a strong foundation for the continued growth of the tumor ablation market. The tumor ablation market is segmented into technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other ablation technologies. By treatment, the market is segregated into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, the market is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, bone cancer, and others.
Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global tumor ablation market are AngioDynamics, Inc., Olympus Corporation, Medtronic Plc, Bioventus Inc.Integra LifeSciences Holdings Corporation, Johnson & Johnson, Boston Scientific Corporation, Stryker Corporation, IceCure Medical Ltd., and Siemens. Key players operating in the market have adopted product approval, agreement, clinical trial, expansion, and acquisition as their key strategies to expand their product portfolio. For instance, in April 2021, Siemens Healthineers AG announced that it successfully completed the acquisition of Varian Medical Systems, Inc. The acquisition was previously announced on August 2, 2020. This acquisition enhanced Siemens Healthineers capabilities in imaging, laboratory diagnostics, artificial intelligence, and treatment solutions, thereby expanding its product portfolio.
For instance, the World Health Organization (WHO), predicted 35 million new cancer cases in 2050, a 77% increase from the estimated 20 million cases in 2022. This growing incidence of cancer increased the demand for effective treatment options, including tumor ablation. Ablation therapies are particularly useful in treating tumors that are difficult to access surgically or those that are located in sensitive areas, such as the liver, lungs, kidneys, and prostate. As the number of cancer patients continues to rise, the need for innovative and less invasive treatment options, such as tumor ablation, are expected to continue to grow. In addition, rise in demand for minimally invasive procedures is another significant driver for the tumor ablation market. As patients and healthcare providers become more aware of the benefits of minimally invasive techniques, such as reduced hospital stays, faster recovery, and fewer complications, the preference for these procedures has grown. Tumor ablation procedures, being minimally invasive, cater to this demand, providing a treatment option that are performed with smaller incisions or even through percutaneous (needle-based) approaches. These factors make tumor ablation particularly appealing to both patients and healthcare providers, leading to a shift toward these therapies in clinical practice. Furthermore, rises in government initiatives aimed at cancer research and treatment are another factor fueling market growth.
Many governments and organizations are increasing funding for cancer-related research, which has led to the development of more effective and precise tumor ablation technologies. The U.S. National Cancer Institute (NCI), for example, has been actively involved in funding studies related to innovative cancer treatments, including tumor ablation. In addition, several regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are working to streamline the approval processes for new tumor ablation technologies, which has encouraged further market development. For instance, in March 2024, Medtronic plc, a global leader in healthcare technology announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. Thus, rise in the number of product approvals further drives market growth. However, high cost of ablation procedures and equipment, which limits accessibility, particularly in low- and middleincome countries, thereby restricts market growth. These procedures often require advanced technology, which can be expensive for healthcare providers to adopt and maintain, making it difficult for many patients to afford. In addition, the limited reimbursement policies in certain regions can restrict patient access to these therapies. Another restraint is the potential for complications associated with ablation procedures, such as injury to surrounding healthy tissues or inadequate treatment of larger or more complex tumors which further limits the market growth.
On the other hand, the ongoing advancements in ablation technologies, such as the development of more precise and efficient devices, create opportunities to improve treatment outcomes and expand the range of treatable tumors. There is also considerable potential for market expansion in emerging economies, where improving healthcare infrastructure and increasing awareness about cancer treatments are driving the adoption of advanced medical technologies such as tumor ablation. These opportunities collectively provide a strong foundation for the continued growth of the tumor ablation market. The tumor ablation market is segmented into technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other ablation technologies. By treatment, the market is segregated into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, the market is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, bone cancer, and others.
Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global tumor ablation market are AngioDynamics, Inc., Olympus Corporation, Medtronic Plc, Bioventus Inc.Integra LifeSciences Holdings Corporation, Johnson & Johnson, Boston Scientific Corporation, Stryker Corporation, IceCure Medical Ltd., and Siemens. Key players operating in the market have adopted product approval, agreement, clinical trial, expansion, and acquisition as their key strategies to expand their product portfolio. For instance, in April 2021, Siemens Healthineers AG announced that it successfully completed the acquisition of Varian Medical Systems, Inc. The acquisition was previously announced on August 2, 2020. This acquisition enhanced Siemens Healthineers capabilities in imaging, laboratory diagnostics, artificial intelligence, and treatment solutions, thereby expanding its product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2023 to 2035 to identify the prevailing tumor ablation market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- Other Ablation Technologies
By Treatment
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
By Application
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Bone Cancer
- Other
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest Of La
Key Market Players
- Bioventus Inc.
- Medtronic Plc
- Johnson & Johnson
- IceCure Medical Ltd.
- Siemens
- AngioDynamics, Inc.
- Stryker Corporation
- Olympus Corporation
- Integra LifeSciences Holdings Corporation
- Boston Scientific Corporation
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY
CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT
CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION
CHAPTER 7: TUMOR ABLATION MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Bioventus Inc.
- Medtronic Plc
- Johnson & Johnson
- IceCure Medical Ltd.
- Siemens
- AngioDynamics, Inc.
- Stryker Corporation
- Olympus Corporation
- Integra LifeSciences Holdings Corporation
- Boston Scientific Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 372 |
| Published | January 2025 |
| Forecast Period | 2023 - 2035 |
| Estimated Market Value ( USD | $ 1.6 billion |
| Forecasted Market Value ( USD | $ 7.5 billion |
| Compound Annual Growth Rate | 13.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
